{"uri": "eng-9423456", "concepts": [{"uri": "http://en.wikipedia.org/wiki/Regeneron_Pharmaceuticals", "type": "org", "score": 100, "label": {"eng": "Regeneron Pharmaceuticals"}}, {"uri": "http://en.wikipedia.org/wiki/Food_and_Drug_Administration", "type": "wiki", "score": 99, "label": {"eng": "Food and Drug Administration"}}, {"uri": "http://en.wikipedia.org/wiki/Diffuse_large_B-cell_lymphoma", "type": "wiki", "score": 67, "label": {"eng": "Diffuse large B-cell lymphoma"}}, {"uri": "http://en.wikipedia.org/wiki/Follicular_lymphoma", "type": "wiki", "score": 44, "label": {"eng": "Follicular lymphoma"}}, {"uri": "http://en.wikipedia.org/wiki/2014_Fed_Cup_Europe/Africa_Zone_Group_III_\u2013_Pool_A", "type": "wiki", "score": 43, "label": {"eng": "2014 Fed Cup Europe/Africa Zone Group III \u2013 Pool A"}}, {"uri": "http://en.wikipedia.org/wiki/Non-Hodgkin_lymphoma", "type": "wiki", "score": 43, "label": {"eng": "Non-Hodgkin lymphoma"}}, {"uri": "http://en.wikipedia.org/wiki/Biologics_license_application", "type": "wiki", "score": 42, "label": {"eng": "Biologics license application"}}, {"uri": "http://en.wikipedia.org/wiki/Nasdaq", "type": "wiki", "score": 34, "label": {"eng": "Nasdaq"}}, {"uri": "http://en.wikipedia.org/wiki/Relapse", "type": "wiki", "score": 34, "label": {"eng": "Relapse"}}, {"uri": "http://en.wikipedia.org/wiki/Disease", "type": "wiki", "score": 34, "label": {"eng": "Disease"}}, {"uri": "http://en.wikipedia.org/wiki/Lymphoma", "type": "wiki", "score": 33, "label": {"eng": "Lymphoma"}}, {"uri": "http://en.wikipedia.org/wiki/Cancer", "type": "wiki", "score": 32, "label": {"eng": "Cancer"}}, {"uri": "http://en.wikipedia.org/wiki/Efficacy", "type": "wiki", "score": 28, "label": {"eng": "Efficacy"}}, {"uri": "http://en.wikipedia.org/wiki/Therapy", "type": "wiki", "score": 25, "label": {"eng": "Therapy"}}, {"uri": "http://en.wikipedia.org/wiki/Tumors_of_the_hematopoietic_and_lymphoid_tissues", "type": "wiki", "score": 23, "label": {"eng": "Tumors of the hematopoietic and lymphoid tissues"}}, {"uri": "http://en.wikipedia.org/wiki/B_cell", "type": "wiki", "score": 23, "label": {"eng": "B cell"}}, {"uri": "http://en.wikipedia.org/wiki/Drug_development", "type": "wiki", "score": 17, "label": {"eng": "Drug development"}}, {"uri": "http://en.wikipedia.org/wiki/Orphan_drug", "type": "wiki", "score": 14, "label": {"eng": "Orphan drug"}}, {"uri": "http://en.wikipedia.org/wiki/European_Medicines_Agency", "type": "wiki", "score": 14, "label": {"eng": "European Medicines Agency"}}, {"uri": "http://en.wikipedia.org/wiki/European_Union", "type": "loc", "score": 14, "label": {"eng": "European Union"}, "location": null}, {"uri": "http://en.wikipedia.org/wiki/Cemiplimab", "type": "wiki", "score": 13, "label": {"eng": "Cemiplimab"}}, {"uri": "http://en.wikipedia.org/wiki/Oncology", "type": "wiki", "score": 13, "label": {"eng": "Oncology"}}], "eventDate": "2024-03-25", "totalArticleCount": 14, "title": {"eng": "FDA issues response letters for Regeneron's cancer drug By Investing.com"}, "summary": {"eng": "TARRYTOWN, N.Y. - Regeneron (NASDAQ:REGN) Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that the U.S. Food and Drug Administration (FDA) has issued Complete Response Letters (CRLs) regarding its Biologics License Application (BLA) for the experimental cancer drug odronextamab.\n\nThe CRLs, which address the drug's use for relapsed/refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL), cited the need for further progress in confirmatory trial enrollment as th"}, "location": null, "categories": [{"uri": "dmoz/Business/Biotechnology_and_Pharmaceuticals/Pharmaceuticals", "label": "dmoz/Business/Biotechnology and Pharmaceuticals/Pharmaceuticals", "wgt": 46}, {"uri": "dmoz/Health/Specific_Substances/Tobacco", "label": "dmoz/Health/Specific Substances/Tobacco", "wgt": 100}, {"uri": "dmoz/Health/Conditions_and_Diseases/Cancer", "label": "dmoz/Health/Conditions and Diseases/Cancer", "wgt": 61}], "articleCounts": {"eng": 14}, "sentiment": 0.1686274509803922, "wgt": 449020800, "relevance": 2}